Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOLMBRAVE
2024-511538-11-00Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, bevacizumab and holmium-166 microspheres in hepatocellular carcinoma (HCC), sponsored by Gustave Roussy. Primary endpoint: Objective response rate at 6 months. Started Feb 2023; status: completed.
02
Drugs
atezolizumabbevacizumabholmium-166 microspheres
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-511538-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511538-11-00.